SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
BG MEDICINE INC
(NQNM:BGMD Last Sale: .92 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (BGMD : $.92)
$19 million Market Cap at September 12, 2013
Biomedics SubIndustry up .00% / Health Industry up .00% Today
Waltham, MA Research Report Earnings Snapshot - Last 08/14/18
Fact Sheet
Financial Statements
Peer Comparison
Annual Reports

Pieter Muntendam, Pres./CEO
December 11, 2012, announced obtaining CE Mark for CardioSCORE(TM) Test in Europe- "Innovative Blood Test for the Prediction of Major Cardiovascular Events Expected to Launch in the First Half of 2013" enabling the commercial sale of the CardioSCORE™ test in the EU and other countries that recognize the CE Mark. Diagnostics company focused on the development and commercialization of novel cardiovascular tests. The CardioSCORE test is the company's patented diagnostic blood test designed to improve risk prediction of major cardiovascular events beyond traditional risk factor assessments, such as the Framingham Risk Score and European SCORE. IPO at $7 February 3, 2011. Raised $35 million, selling 5 million shares, 27% of the outstanding. Lead Manager: Lazard Ltd.
Historical Charts    Technical Analysis
No Historical Data available for BGMD

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common BGMD $.92 $ 0 $.9026 $.935 26,198 $.8299 $4.48 20,141
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $18,530

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex